People in the News
Tom Daniel and Mark Carthy did not stand for re-election to the board of directors of Solexa at the company's June 7 annual stockholders' meeting, Solexa said in an SEC filing. The two directors informed the board of their decisions on June 3, the company said. Daniel is a founder and partner of Life Science Capital, an investment management business. He has an MBA from Harvard Business School and an undergraduate degree in biological sciences from the University of Oxford. Carthy is a venture partner at Oxford Bioscience Partners. He holds an MBA from Harvard Business School, an MS in chemical engineering from the University of Missouri and a BE in chemical engineering from University College, Dublin in Ireland.
William Gerber and Frank Jellinek have joined the board of directors of Nanogen, while Val Buonaiuto has retired from the board, the San Diego-based company said last week. Gerber is a partner at Bay City Capital, a life sciences investment fund. Most recently, he was president and chief executive officer of Epoch BioSciences, which merged with Nanogen in late 2004.
Jellinek is currently chairman emeritus of Fisher Scientific International and was formerly the president, chief executive officer, and a director of Apogent Technologies until it was acquired by Fisher in 2004.
New Product Watch
Kreatech Biotechnology last week launched its series of Universal Linkage System arrayCGH labeling kits for array-based comparative genomic hybridization analysis.
The kits use an arrayCGH-optimized version of Kreatech's ULS labeling molecule bound to a choice of fluorescent dye pairs in order to label genomic DNA in a one-step labeling reaction.
Kreatech currently offers CyDyes from GE Healthcare, Cyanine Dyes from Perkin Elmer, and DYDyes from Dyomics with its kits, which also include its KreaPure purification columns, its KreaBlock blocking buffer, and hybridization buffers.
SuperArray Bioscience last week launched its new GEArray personalized microarray program, which allows researchers to individually tailor the gene content on low-density microarrays with any set of human, mouse, or rat genes, the company said.
The custom arrays combine a nylon matrix with SuperArray's DNA binding capacity and technologies for array labeling and chemiluminescent detection.
David Martz, SuperArray's director of marketing and sales, said the platform was ideal for "initial experiments or larger screening and validation projects."